Member Policies - Medical Policies - Alabama
Policies & Guidelines
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Genetic Testing Management
- Hemophilia Drug Management
- Medical Policies
- PET, MRI, MRA, CT, CTA/CCTA
- Provider-Administered Drug Policies (Excluding Oncology)
- Provider-Administered Oncology Drug Policies
- Radiation Therapy Management (RTM)
- Self-Administered Drug Policies
- Transgender Services
Current Provider-Administered Oncology Drug Policies
-
Kymriah: For dates of service on or after January 1, 2019, through December 31, 2020, providers or facilities need to send requests and/or claims to Original Medicare. See Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N).
-
Yescarta: For dates of service on or after January 1, 2019, through December 31, 2020, providers or facilities need to send requests and/or claims to Original Medicare. See Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N).
| Policy # | Policy Title | Print View |
|---|---|---|
| VP-0461 | Mvasi™ (bevacizumab-awwb) (Intravenous) | |
| VP-0482 | Polivy™ (polatuzumab vedotin-piiq) (Intravenous) |
Node: bclrgrpappp1001.corp.bcbsal.org:8080